Drugs / 33A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02785900 | May 2016 → Oct 2017 | acute myeloid leukemia | Seagen Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 33A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02785900 ↗ |
| Known as | vadastuximab talirine, SGN-CD33A | “vadastuximab talirine, SGN-CD33A” NCT02785900 ↗ |
| Route | Intravenous | “via intravenous (IV) push” NCT02785900 ↗ |